ChitogenX (TSE:CHGX) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
ChitogenX Inc., a clinical-stage regenerative medicine company, has reported a decrease in net loss and a significant reduction in research and development (R&D) as well as administrative expenses for the second quarter of 2025. The company is actively seeking development partners and funding for regulatory development, while strategically advancing grant-supported research. These efforts are part of ChitogenX’s commitment to its novel therapeutic tissue repair technologies and to securing non-dilutive funding sources.
For further insights into TSE:CHGX stock, check out TipRanks’ Stock Analysis page.
